136 related articles for article (PubMed ID: 24063059)
1. On the MTD paradigm and optimal control for multi-drug cancer chemotherapy.
Ledzewicz U; Schättler H; Gahrooi MR; Dehkordi SM
Math Biosci Eng; 2013 Jun; 10(3):803-19. PubMed ID: 24063059
[TBL] [Abstract][Full Text] [Related]
2. Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy.
Ledzewicz U; Maurer H; Schättler H
Math Biosci Eng; 2011 Apr; 8(2):307-23. PubMed ID: 21631132
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.
West J; Newton PK
Cancer Res; 2017 Dec; 77(23):6717-6728. PubMed ID: 28986381
[TBL] [Abstract][Full Text] [Related]
4. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
Ledzewicz U; Schättler H
Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
[TBL] [Abstract][Full Text] [Related]
5. Array of translational systems pharmacodynamic models of anti-cancer drugs.
Ait-Oudhia S; Mager DE
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
[TBL] [Abstract][Full Text] [Related]
6. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs.
Yoon N; Vander Velde R; Marusyk A; Scott JG
Bull Math Biol; 2018 Jul; 80(7):1776-1809. PubMed ID: 29736596
[TBL] [Abstract][Full Text] [Related]
7. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations.
Ferrer F; Fanciullino R; Milano G; Ciccolini J
Clin Pharmacol Ther; 2020 Sep; 108(3):458-470. PubMed ID: 32557660
[TBL] [Abstract][Full Text] [Related]
8. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
Arora G; Bairagi N; Chatterjee S
Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer.
Rodon J; Pérez-Fidalgo A; Krop IE; Burris H; Guerrero-Zotano A; Britten CD; Becerra C; Schellens J; Richards DA; Schuler M; Abu-Khalaf M; Johnson FM; Ranson M; Edenfield J; Silva AP; Hackl W; Quadt C; Demanse D; Duval V; Baselga J
Cancer Chemother Pharmacol; 2018 Aug; 82(2):285-298. PubMed ID: 29882016
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
12. A memetic algorithm for multiple-drug cancer chemotherapy schedule optimization.
Tse SM; Liang Y; Leung KS; Lee KH; Mok TS
IEEE Trans Syst Man Cybern B Cybern; 2007 Feb; 37(1):84-91. PubMed ID: 17278562
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
15. Gompertz model with delays and treatment: mathematical analysis.
Bodnar M; Piotrowska MJ; Foryś U
Math Biosci Eng; 2013 Jun; 10(3):551-63. PubMed ID: 23906135
[TBL] [Abstract][Full Text] [Related]
16. A mathematical model of chromosome recombination-induced drug resistance in cancer therapy.
Yang HL; Lei JZ
Math Biosci Eng; 2019 Aug; 16(6):7098-7111. PubMed ID: 31698605
[TBL] [Abstract][Full Text] [Related]
17. Modeling multi-drug chemotherapy: tailoring treatment to individuals.
Gardner SN
J Theor Biol; 2002 Jan; 214(2):181-207. PubMed ID: 11812172
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
20. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
